(Q24625246)
Statements
Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression (English)
0 references
August 2011
0 references
85
0 references
16
0 references
8328-37
0 references